Showing posts with label Bio-Treat. Show all posts
Showing posts with label Bio-Treat. Show all posts
| 0 comments ]

'Bio-Treat trades at less than one third of its NAV and maybe four times earnings. That's what I call a giveaway valuation.'
-“Mr Shah- Shah Capital “

This ‘water-play’ has lot of value if not being play down by convertible bonds issue.
As there is news that BIO-TREAT Technology is in advanced discussions to get a bank loan to settle the convertible bondholders, the reversal may come home not too far now.

My personal accumulation will start when STI hit a new low in coming days.


Continue to read more...
| 0 comments ]

Bio-Trick have outstanding convertible bonds of about 909.5 million renminbi and these bond holders have exercised their bond’s put option since January 2008.

Bio-Trick has to sort out the refinancing of its convertible bonds as soon as possible. The share price has slide from over one dollar mark to as low as 15 cents today.

It is interesting to observe how creative financial engineering can rescue once the market darling in the good times.

Share placement/ Right Issue/Warrant Issue
- Highly dilutive in today’s share price. How many share they have to issue to raise that amount? If Bio-Trick still trading at $1 mark, all problems shall have been resolved long ago with this method.

Setup public-listed business trust
- The management claimed that there are ‘some enquires from pension funds in Europe and the US’ who are looking for long-term and consistent returns. These sound fantastic but why Bio-Trick? Why not Hyflux with similar business trust, proven track record, strong parent backing, large capitalization and idol CEO ?

White Knight
- Not heard of after the death of the white knight from Hong Kong. Lehman Brothers also looking for one now.

Bridging loan
- Will you loan to a stranger deeply in debt? While, no way, not even you are running a charitable fund. Even if the loan deal is on, Bio-Trick is expected to service the interest for many years to come.

Asset Sale
- Strip the asset for fire sale one by one.

In my guess, the combination of asset sale with bridging loan is the most likely outcome. Of course, we will see the gloom face of many
shareholders.

This article is not means to advise or encourage you to buy/sell or to do whatsoever. Caveat emptor!


Continue to read more...
| 0 comments ]

Hyflux Water Trust (HWT) has reported distributable cash of $4.5 million for the first half of the year. HWT is forecasting full-year DPU of 4.88 cents, reflecting a yield of about 7.7 per cent.

In another front, Bio-Treat is looking into setting up a similar business trust that will contain all its water-related infrastructure assets. Bio-Treat is in dirt need of cash to repay $206 million debts owed to its convertible bond holders.

In comparison to HWT with a reputable sponsor of Hyflux Limited, Bio-Treat has an uphill task to entice investors to park money with its new trust, especially to beat the 7.7% high yield projection with HWT.

The target to raise $250 million to $350 million from the new trust is more than Bio-Treat’s current market capitalization of $250 million. Since they intend to hold 30% of trust upon listing, they are likely overvalued the 70% stake of their assets.

The actual valuation should be at the lower bound or below $200 million in order to push up the yield percentage in view of the market competition. Bio-Treat is unlikely to get excess cash for future investment too after paying their convertible bond holders.

I am not investing in Bio-Treat new business trust if the yield is not significant better then HWT’s 7.7%.

Continue to read more...